Thermo Fisher’s warning on more pain from biotech funding squeeze hits sector
By Bhanvi Satija (Reuters) -Thermo Fisher Scientific on Wednesday signaled that a slump in demand from biotechs for its services used in making therapies and vaccines could extend into the next year, sending its shares tumbling more than 7% and weighing on the sector. Biotechs, hit by a funding crunch due to higher interest rates,…
